Results 141 to 150 of about 7,117 (221)

Considerations for the practical management of cardiovascular risk with Bruton's tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia. [PDF]

Oncologist
Lenihan D, Bloom M, Copeland-Halperin R, Fleming MR, Fradley M, O'Quinn R, Bhat SA.   +6 more
europepmc   +1 more source

BTK inhibitors potently impair platelet aggregation as a class effect independent of BTK specificity or dose in CLL and MCL. [PDF]

J Clin Exp Hematop
Kojima K, Watanabe S, Takeuchi A, Kunisawa N, Yoshida S.   +4 more
europepmc   +1 more source

How well does acalabrutinib work and how safe is it to treat patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have had previous treatments? a plain language summary of 2 key studies. [PDF]

Future Oncol
Byrd JC, Hakre S, Ghia P.
europepmc   +1 more source

Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS). [PDF]

Ann Hematol
Quinquenel A, Leprêtre S, Dilhuydy MS, Bussot L, Marjanovic Z, Benbrahim O, Guièze R, Santagostino A, Dartigeas C, Feugier P, Roos-Weil D, Damaj G, Laribi K, Ysebaert L, Levy V.   +14 more
europepmc   +1 more source

Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study. [PDF]

Cureus
Ito A, Ito K, Iriyama C, Goto N, Inamoto Y, Okamoto M, Hirose Y, Morisaku M, Yamada S, Hayakawa N, Tomita A.   +10 more
europepmc   +1 more source

The Brief Case: Cutaneous ulceration associated with acalabrutinib treatment

Journal of Clinical Microbiology
Victor Luzarraga, Céline Nourrisson, Florence Anglade, Carole Chevenet, Philippe Poirier, Maxime Moniot   +5 more
doaj   +1 more source

Ibrutinib <i>versus</i> acalabrutinib in fixed-duration chronic lymphocytic leukemia therapy: a comparative analysis of efficacy. [PDF]

Haematologica
Molica S, Shanafelt TD, Giannarelli D, Allsup D.   +3 more
europepmc   +1 more source

Zanubrutinib in the treatment of Waldenström Macroglobulinemia. [PDF]

Future Oncol
Goodall E, Opat S.
europepmc   +1 more source

The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia. [PDF]

Curr Issues Mol Biol
Saleh K, Arbab A, Khalife N, Khoury R, Ibrahim R, Hachem MA, Khalil C, Bou Orm C, Sawan J, Lafarge G, Masri N, Tikriti Z, Chahine C, Le Cesne A.   +13 more
europepmc   +1 more source

Rapid response of omalizumab-resistant chronic urticaria to acalabrutinib

JAAD Case Reports
Diamond R. Guy, BS, Alicia Mizes, MD, Christopher T. Richardson, MD, PhD   +2 more
doaj   +1 more source